Press Releases

TORONTO, Sept. 14, 2026 /CNW/ -- Blue Moon Metals Inc. ("Blue Moon" or the "Company") (TSXV:MOON) (NASDAQ:BMM), along with The Elmet Group Co. ("Elmet" or "TEG") (NASDAQ:ELMT), and EQ Resources Limited ("EQ") (ASX: EQR) (together the "Parties" or "Party"), are pleased to announce signing a binding letter agreement dated September 11, 2026 regarding a series of strategic transactions intended to unlock the value of Blue Moon's Springer Tungsten Complex ("Springer"), located in Imlay, Nevada.Springer historically was one of the largest tungsten mines in the United States, and consisting of open pit and underground mines, a 1,200 Tpd mill and an Ammonium Paratungstate ("APT") plant capable of p

PORTLAND, Maine, Sept. 14, 2026 (GLOBE NEWSWIRE) -- The Elmet Group Co. (NASDAQ:ELMT) ("ELMT" or the "Company"), a U.S.-based provider of critical materials, precision-engineered components, and advanced high-energy systems, plans to allocate capital from the $450 million committed investment from the United States Department of War ("DoW") to establish a more secure, vertically integrated tungsten supply chain while expanding domestic manufacturing and strengthening sources of critical minerals. The anticipated investments are designed to strengthen America’s tungsten supply chain by expanding domestic manufacturing, securing long-term access to critical raw materials, and establishing a

Investment expected to enhance domestic manufacturing capacity and reduce foreign dependence on critical minerals Anticipated to expand ELMT’s resilient global tungsten mining network and processing capabilities ELMT secures up to $2 billion agreement to support the National Defense Stockpile Company to host investor call today at 9 a.m. ET PORTLAND, Maine, Sept. 14, 2026 (GLOBE NEWSWIRE) -- The Elmet Group Co. (NASDAQ:ELMT) ("ELMT" or the "Company"), a U.S.-based provider of critical materials, precision-engineered components, and advanced high-energy systems, today announced a $450 million committed investment from the United States Department of War ("DoW") to accelerate ELMT’s U.S.

Board Authorization Reflects Confidence in Solidion's Long-Term Strategy and Commitment to Enhancing Shareholder ValueDALLAS, Sept. 14, 2026 /CNW/ -- Solidion Technology, Inc. (NASDAQ:STI) ("Solidion Technology" or "the Company"), an advanced battery technology solutions provider, today announced that its Board of Directors ("the Board") has authorized a new stock buyback program, pursuant to which the Company intended to buyback up to $1.0 Million of the Company's outstanding common stock. The stock buyback program became effective on September 13, 2026 and will remain in effect until (i) the date on which the full amount auth

Ambassador Kirsten Hillman appointed as Lead Strategic Advisor for Scotia Growth Institute TORONTO, Sept. 14, 2026 /CNW/ -- Scotiabank today announced the launch of the Scotia Growth Institute—a new platform dedicated to supporting key stakeholders in advancing long-term economic growth and competitiveness in Canada and across North America. The Institute will draw on Scotiabank's expertise, insights, and partner and client perspectives from high-growth sectors to guide policymakers, business leaders, and markets in making decisions about Canada's long-term competitiveness, and to bring greater focus to the economic choices ahe

AUSTIN, Texas, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Digital Realty (NYSE:DLR), the world’s largest cloud- and carrier-neutral data center platform, and Rönesans Infrastructure, one of the largest investment companies in Türkiye and a top 50 international contractor on ENR International Contractors List, today announced the formation of a strategic joint venture (JV) to develop and operate next-generation data centers across Türkiye. The JV extends PlatformDIGITAL® into the Turkish market, supporting the continued growth of the country's digital economy and increasing demand for cloud, AI, connectivity, and enterprise digital infrastructure. Positioned at the crossroads of Europe, the Middle

Today, Venture Global, Inc. (("Venture Global", NYSE:VG) and China Gas Holdings Limited ("China Gas"; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030.This SPA brings Venture Global’s current long-term offtake with China Gas, to 2.5 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to expand our LNG partnership with China Gas, a leading natural gas operator in China, supplying the country's growing energy needs with reli

MSCI survey finds 71% of advisers plan to increase their use of active ETFs over the next two years58% say a new active ETF allocation would most likely displace an existing mutual fund45% of respondents expect to broaden their equity allocations beyond their home markets over the next two yearsNearly half are open to accessing less liquid assets through an ETF, but only 16% think private markets are a good fit for the structureNEW YORK, Sept. 14, 2026 /PRNewswire/ -- Active ETFs are firmly in the mainstream and set for further growth, but advisers are putting greater emphasis on value, liquidity and structural fit when deciding which products earn a place in portfolios, according to a surve

Gotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year1Gotistobart demonstrated a median overall survival of 18.5 months compared to 10.0 months with standard-of-care chemotherapy in updated data from stage 1 of the PRESERVE-003 Phase 3 clinical trial, nearly doubling median survival in this patient populationFindings are consistent with gotistobart’s differentiated mechanism of action as an investigational immunomodulator that selectively enhances regulatory T cell depletion through CTL

Global semiconductor revenue surpassed $425bn in 2Q26 reaching another all-time high as the market grew a record 31.4% quarter-over-quarter (QoQ) , according to new research from Omdia. AI demand and strong memory prices continued to be the leading market dynamics, taking total semiconductor revenue for the first half of 2026 to $752 billion. The 31.4% QoQ increase surpassed the previous sequential growth record of 29.2% in 1Q26. Since Omdia began tracking the semiconductor market in 1Q02, only 10 out of 97 quarters have recorded sequential revenue growth above 10%. The last four quarters beginning in 3Q25, have all recorded double-digit sequential growth, with 3Q26 expected to follow the s

Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda ((TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-g

Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by continuing existing cell therapy partnerships while exiting lasme-cel and eti-cel developmentRealignment of the operating model targeting Cellectis cash runway extension into H2 2028Conference call and webcast on September 14: English at 8 a.m. ET, French at 9 a.m. ET NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo

Rapid commissioning operations unlock scarce, very high-resolution imaging capacity as global demand for responsive, tactical space‑based intelligence accelerates BlackSky Technology Inc. (NYSE: BKSY) collected and processed first light imagery from its fifth Gen‑3 satellite in less than 20 hours after liftoff, demonstrating a consistent launch-to-launch pattern of rapid data delivery timelines that significantly outpace the industry standard. Rapid commissioning means customers gain immediate access to mission‑ready, very high‑resolution imagery amid fast-moving operational environments that demand real-time situational awareness to see, understand and act with confidence. This press re

STMicroelectronics introduces automotive image sensorto help scale affordable in-cabin sensing Helps OEMs and Tier 1s bring driver and occupant monitoring to high-volume vehicle platforms with lower system costDelivers 35% higher image sharpness and nearly 60% higher infrared sensitivity than the previous generation in a compact 1.1 MP automotive image sensor Geneva, Switzerland, September 14, 2026 – STMicroelectronics (NYSE:STM), a global semiconductor leader serving customers across the spectrum of electronics applications, introduces ST SafeSense VD56GA, a new 1.1 MP automotive image sensor for infrared in-cabin sensing that helps OEMs and Tier 1 suppliers scale driver and occupant moni

All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients’ prior course of radiotherapyInvestigators concluded that JNJ-1900 (NBTXR3 may permit clinically meaningful local control using a substantially lower re-irradiation dose than patients’ prior course of radiotherapyEnrollment in the dose-escalation and expansion parts o

Funding Commitment: Signing of binding agreement provides for up to USD1 billion in combined equity commitments from Space42 and Viasat as the initial co-founders of EquatysProgram Progression: Simultaneous signing of agreement to step-up funding accelerates program development of the initial satellite constellation; Scalable constellation’s initial tranche to be awarded upon formation of Equatys with planned appointment of Viasat as prime technology contractorStrategic Differentiation: Equatys intended to offer a foundation for choice and interoperability and provide compelling economic benefits from geographic and spectral efficiencies to participating global, regional and national space o

6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapy AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-m

Longest survival data ever reported in a global Phase III trial in this setting New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. These results were presented today during the Presidential Symposium at the I

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and METResults mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8%SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) muta

Represents a six-month improvement in median progression-free survival versus pembrolizumab plus chemotherapy Daiichi Sankyo and AstraZeneca’s Enhertu is the first HER2 directed medicine to delay disease progression over standard of care in a phase 3 trial in this setting Positive results from the DESTINY-Lung04 phase 3 trial showed Enhertu® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a first-line treatment of patients with unresectable, locally advanced or metastatic HER2 mutant non-squamous non